Full-Time

Associate Director Validation

Biopharma

Confirmed live in the last 24 hours

Agilent Technologies

Agilent Technologies

10,001+ employees

eProcurement services for streamlined purchasing

Compensation Overview

$150k - $234.4k/yr

+ Bonus + Stock

Senior, Expert

Company Does Not Provide H1B Sponsorship

Fort Lupton, CO, USA

Category
Biology Lab & Research
Biology & Biotech
Required Skills
Management
Requirements
  • Bachelors or Master’s degree or University Degree or equivalent in Engineering or equivalent combination of education and or experience preferred.
  • 5+ years of experience in management with at least 4 direct reports within a cGMP production facility preferred.
  • 10+ years of equivalent experience in validation and or engineering in a pharmaceutical and/or Biologics area required.
  • Demonstrated strong management and leadership skills in implementing program/organization strategies.
  • Experience with leading and setting policy for cleaning validation; preferably in API and or Biologics.
  • Experience with defending a validation program with Boards of Health.
  • Independent problem solving and the ability to drive a team to support an ongoing cGMP Operation.
  • Experience working with cross-functional groups and leading projects through a matrix of resources to complete.
Responsibilities
  • Provide leadership in Validation to ensure Nucleic Acid Solutions Division (NASD) sites meet the regulatory expectations for cGMP manufacture of the product and are aligned with industry expectations.
  • Set direction and provide leadership in the areas of cleaning validation, equipment qualification, computer systems validation, and all other aspects of the Validation Programs for NASD.
  • Set policy and drive results for the cleaning validation program for NASD.
  • Manages, approves, and generates validation documentation including protocols, plans, reports, and addenda.
  • Management of validation life cycle to ensure ongoing validated state of systems through oversight of the execution of validation studies for cleaning and equipment qualification as required.
  • Responsible for the Master Validation Plan (MVP) and all related documentation.
  • Managerial responsibilities include the development of reports and team through mentoring and training with the objective to have a cross-functional group that works well in a team environment.
  • Scheduling, advising activities, budgeting, and hiring for the department.
  • Set strategic and technical goals for the validation team to provide continuous improvement in the areas of cleaning validation, equipment qualification, and computer validation driving policy to align with regulatory and industry expectations.
  • Serves as a liaison and cross-functional lead with Quality Assurance to provide an overall compliant facility with the highest level of service.
  • Provide direction and set goals to ensure compliance with the Quality Management System for Validation ensuring a state of inspection readiness.
  • Serve as the lead for Validation during client audits and regulatory inspections.
  • Act as a delegate for AVP of Engineering and Facilities and other Validation Managers in aspects of Validation.
Desired Qualifications
  • Bachelors or Master’s degree or University Degree or equivalent in Engineering or equivalent combination of education and or experience preferred.
  • 5+ years of experience in management with at least 4 direct reports within a cGMP production facility preferred.

Agilent Technologies provides electronic procurement services that help businesses streamline their purchasing processes. Their suite of eProcurement services allows clients to integrate their pricing into existing platforms, access a hosted catalog, and conduct transactions without paper. This system is designed to help businesses quickly find and purchase the products they need at the right price, enhancing productivity through automation and simplified workflows. Agilent stands out from competitors by focusing on reliability and quality, serving a diverse range of clients who benefit from their expertise. The company's goal is to lower costs and increase profitability for its clients by improving efficiency in procurement.

Company Size

10,001+

Company Stage

IPO

Headquarters

Santa Clara, California

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisitions like Sigsense enhance Agilent's AI capabilities in lab operations.
  • The trend towards paperless transactions boosts Agilent's service efficiency and appeal.
  • Automation in procurement is expected to increase, benefiting Agilent's offerings.

What critics are saying

  • Integration challenges from acquiring BIOVECTRA may disrupt Agilent's operations.
  • Multiple acquisitions could stretch Agilent's resources and management focus.
  • Increased competition from funded companies like RareCyte and Elegen may challenge Agilent.

What makes Agilent Technologies unique

  • Agilent offers a comprehensive suite of eProcurement services for streamlined purchasing.
  • The company focuses on automation and paperless transactions to enhance business productivity.
  • Agilent's hosted catalog and pricing integration simplify procurement processes for clients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Performance Bonus

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

6%

2 year growth

5%
Business Wire
Jul 30th, 2024
Agilent Acquires Sigsense, Creator of AI-Enabled Lab Operations Technology

Agilent has acquired Sigsense Technologies, a startup that uses artificial intelligence and power monitoring to optimize lab operations.

Biovectra
Jul 22nd, 2024
Agilent Technologies to Acquire BIOVECTRA Inc., Creating New Synergistic Opportunities to Improve Patient Care | BIOVECTRA

CHARLOTTETOWN, Prince Edward Island and SANTA CLARA, California – July 22, 2024 BIOVECTRA Inc. and Agilent Technologies, Inc. (NYSE: A) today announced the signing of an agreement for Agilent to acquire BIOVECTRA, a Canadian-based Contract Development and Manufacturing Organization, from H.I.G. Capital for $925 million. The acquisition provides the ability to expand the range of [...]Read More...

Finsmes
Jun 27th, 2024
RareCyte Secures $20M Financing

RareCyte, a Seattle, WA-based Life Sciences company providing precision biology platforms including instruments, reagents, software, and services, raised $20M in funding

Business Wire
May 14th, 2024
Elegen Raises $35 Million In Series B To Accelerate Expansion Into Clinical Manufacturing

SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen, the leader in next-generation DNA synthesis and production, today announced a Series B financing of $35 million led by Triatomic Capital. Also joining the round are strategic investors GSK, which recently entered a collaboration and licensing agreement with Elegen to use their proprietary cell-free DNA manufacturing technology in developing GSK’s vaccines and medicines, and John Ballantyne, co-founder of Aldevron. Elegen’s current investors, including Andreessen Horowitz (a16z Bio + Health), KdT Ventures, 8VC, Digitalis Ventures, ACVC Partners, Alix Ventures, AME Cloud Ventures and Agilent Technologies, also participated. The new funds will accelerate the extension of the company’s rapidly growing ENFINIA™ DNA product line across clinical workflows providing turnkey production of GMP-compliant DNA for clinical development of genetic medicines. “The age of genetic medicines is here, but these powerful modalities require innovative new manufacturing approaches to supply the critical input DNA material for rapid discovery, development and then wide-scale production,” said Matthew Hill, Ph.D., Elegen Founder and CEO. “With this investment, we will continue to push the boundaries of DNA synthesis to accelerate upstream discovery and enable rapid and streamlined deployment of new clinical modalities.”

GenomeWeb
Apr 3rd, 2024
Biofidelity Raises $24M to Expand US Commercialization of Lung Cancer Test, Product Pipeline

The firm said it also plans to use the money, which brings its total raised to $60 million, to establish a dedicated manufacturing facility in the UK.